Using a BRET-based shift assay, the system quantifies target engagement in intact cells, including weak interactions, broadening drug discovery workflows and improving early-stage confidence in ...

When we hear that a person has quirks, we expect to be charmed. But when we hear that a cell-based assay has quirks, we expect to be frustrated. Quirks in cell-based assays tend to complicate drug ...

Scientists use multi-day live cell assays to monitor cell growth, viability, and cytotoxicity when evaluating the effects of drug treatment. However, maintaining consistent cell health over time ...

In the immuno-oncology field, scientists discover, test, and validate novel immunotherapeutic agents that leverage the human immune system to fight cancer, such as checkpoint inhibitors, vaccine-based ...

This article and associated images are based on a poster originally authored by Zhong Yu, Parker Ellingson, Denise Sullivan, Ben Streeter, Austin Passaro, Stacie Chvatal and Daniel Millard and ...

Cell-Based Assays are expanding post-pandemic, driven by new tech enabling comprehensive cell function measurements. They're pivotal in biotech, with growth fueled by advancements in genomics and ...

Gregory Russotti is the Chief Technology and Manufacturing Officer at Century Therapeutics, a company developing iPSC-derived, allogeneic immune cell therapy products for hematology/oncology ...

This article is based on a poster originally authored by Yongyang Huang, Ning Guo, Mackenzie Pierce, Leo Chan, Bo Lin and Yi Yang, which was presented at ELRIG Drug Discovery 2024 in affiliation with ...

In the ever-evolving landscape of biomedical research, the need for reliable, consistent, and ready-to-use cell models has never been more critical. ATCC, a leading provider of biological materials, ...

Tom Congdon (left) is the CEO and Co-Founder of CryoLogyx (Coventry, UK), a University of Warwick (UK) spinout that develops technology for cryopreservation of cell-based assays and novel ...